KEYNOTE 522 is the fourth study of a KEYTRUDA-based regimen in an earlier stage of cancer to demonstrate an OS benefit, in addition to KEYNOTE-A18 in cervical cancer, KEYNOTE-671 in non-small cell lung cancer and KEYNOTE-564 in...
The KEYNOTE-522 trial is the first randomised phase 3 trial of an immune checkpoint inhibitor in early triple negative breast cancer. We've seen data in metastatic triple negative breast cancer with immune checkpoint inhibitors showing a clear benefit in survival. When it comes to early triple ...
在TNBC中,基于KEYNOTE-522的阳性结果,帕博利珠单抗已经被批准用于新辅助治疗(N Engl J Med. 2020; 382:810-821)。在ESMO 2023大会上,报告了KEYNOTE-522(LBA18)的长期更新数据。中位随访63.1个月后,新辅助帕博利珠单抗加化疗再辅以帕博利珠单抗治疗结果显示,无论患者是否达到pCR,与单独新辅助化疗相比,EFS均得到...
5. H. K. Ahn et al., Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer: The Neo-PATH Phase 2 Nonrandomized Clinical Trial. JAMA Oncology 8, 1271-1277 (2022). 解读者介绍 邵营...
(NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Phase 3 KEYNOTE-671 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, met one of its dual primary endpoints, event-free sur...
The chemotherapy regimen chosen in this trial was what I would describe as the most effective chemotherapy regimen we have at the moment. That is really important, because the benefit of pembrolizumab, shown on top of that, is even more relevant....
While our rate of pCR is lower than the findings of the Keynote-522 trial; 52.5 % (95% CI: 38% - 69%) vs. 64.8% (95% CI: 59.9%-69.5%), our sample size is not large enough to detect a statistically significant difference. Sub-analysis of patient ethnicity demonstrated varying ...
Peter Schmid, MD, PhD, discusses his key takeaways from the phase 3 KEYNOTE-522 trial and the updated findings presented at the 2024 ESMO Congress. Peter Schmid, MD, PhD, of Barts Cancer Institute at Queen Mary University in London, United Kingdom, discusses his key takeaways from thephas...
However, the KEYNOTE 522 trial has demonstrated improved outcomes with the incorporation of the PD-1 inhibitor Pembrolizumab alongside neoadjuvant chemotherapy.Methods:A retrospective cohort analysis of 106 patients treated with the KEYNOTE 522 regimen within Cleveland Clinic from January 2020 to July ...
Hepatocellular Carcinoma KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containin...